Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Melissa BadamoAcute Lymphoblastic Leukemia | May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Melissa BadamoPrint | May 7, 2025
The awards recognize early-, mid-, or senior-career experts who display excellence in the field.
Nichole TuckerAcute Lymphoblastic Leukemia | May 6, 2025
During The HemOnc Pulse Live! Nick Short, MD gave a presentation on unanswered questions in ALL.
Andrew MorenoTransplantation & Cellular Therapy | April 25, 2025
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Melissa BadamoAcute Lymphoblastic Leukemia | April 23, 2025
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
Advertisement
Melissa BadamoPrint | April 14, 2025
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Melissa BadamoVideo Insights | April 15, 2025
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
Melissa BadamoAcute Lymphoblastic Leukemia | April 8, 2025
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Nichole TuckerAcute Lymphoblastic Leukemia | April 15, 2025
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
Andrew MorenoTransplantation & Cellular Therapy | March 31, 2025
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Andrew MorenoAcute Lymphoblastic Leukemia | March 14, 2025
Measurable residual disease has a prominent role in risk assessment, prognosis, and management decisions in T-ALL and B-ALL.
Melissa BadamoAcute Lymphoblastic Leukemia | March 14, 2025
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
Melissa BadamoAcute Lymphoblastic Leukemia | March 10, 2025
CTD402 will be studied in a single-arm, open-label, phase 1b/2 trial with a simplified dose-finding design.
Melissa BadamoAcute Lymphoblastic Leukemia | February 4, 2025
The approval is based on the E1910 trial, which compared blinatumomab and consolidation chemotherapy with chemotherapy alone.
Andrew MorenoT-Cell Lymphoma | January 30, 2025
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
Melissa BadamoAcute Lymphoblastic Leukemia | January 27, 2025
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
Andrew MorenoAcute Lymphoblastic Leukemia | January 22, 2025
A real-world study found blinatumomab plus ponatinib as more likely to be effective if used in earlier lines of therapy.
Andrew MorenoAcute Lymphoblastic Leukemia | January 10, 2025
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
Andrew MorenoTransplantation & Cellular Therapy | January 6, 2025
A compound to assist CAR T-cell therapy by targeting and suppressing YTHDF2 is in development.
Advertisement
Advertisement